En


EFMC Sponsored Event

April 14-15, 2020
San Francisco, United States

The identification of potential new therapeutic agents is met with significant challenges in preclinical discovery and development.  Both efficacy and safety endpoints must be adequately assessed prior to testing a new investigational agent in humans.  Perhaps the most challenging part of drug discovery is the mitigation of safety risks that arise during most drug discovery optimization efforts.  In order to design and make safer drug candidates, medicinal chemists work with cross-functional drug discovery partners to understand, assess and mitigate safety risks associated with potential new drug candidates.  Successful drug discovery teams will properly design and execute experiments that can best assess and discharge risks prior to first human dose (FHD).  This must be accomplished in the context of anticipated human drug exposures and patient risk-benefit analysis.  Through the lens of modern medicinal chemistry, this course explores the current best practices and methods used to identify, understand and mitigate common preclinical safety risks from both a strategic and tactical perspective.  Importantly, the course also describes proactive approaches that can help medicinal chemists avoid many safety issues and deliver safer small molecule drug candidates.  A key objective of the course is to improve medicinal chemist’s preparedness for participation and leadership on cross-functional drug discovery teams.

Course Outline:

  • Principles of toxicology and safety assessment.
  • The Investigational New Drug (IND) application.
  • Target assessment, predictive toxicology and in silico methods.
  • Preferred drug properties to minimize toxicological risks.
  • Common off-target safety concerns and mitigation.
  • Managing on-target safety concerns.
  • Pharmacokinetics in preclinical safety assessment.
  • Drug metabolism and bioactivation.
  • Toxicophores and Structure Alerts.
  • Mechanisms and mitigation strategies for Drug-Induced Liver Injury (DILI).
  • Preclinical safety biomarkers and translation to the clinic.
  • Clinical candidate selection and FHD enablement.

For more information contact: 

April 16-19, 2020
İstanbul, Turkey

For more information please contact : oyaunsal@hacettepe.edu.tr

Organised by:
  • Turkish Association of Medicinal and Pharmaceutical Chemistry (Turkey)


EFMC Sponsored Event

April 21, 2020
London, United Kingdom

Nucleosides are key structures for current drug development and have established roles as antivirals and anticancer agents. Their (poly)phosphorylated nucleotide counterparts are critical tools for chemical biology and sequencing technologies. In recent years, nucleotides have also become fundamental building blocks for the preparation of altered genes and coding systems for synthetic biology. This meeting seeks to explore and celebrate the chemistry that drives the development of modern nucleoside and nucleotide chemistry. It will bring together scientists who work at the interfaces of synthetic and biological chemistry to deliver new tools and insights for biology, and new leads for drug development.

Features of the Meeting
• Synthetic methodologies for the preparation of nucleosides, nucleotides and related molecules
• Applications for nucleosides and nucleotides as medicines
• Applications of nucleosides and nucleotides as tools for chemical biology and synthetic biology
• Plenary speakers, poster session and trade exhibition

Deadline for abstract submission for oral communication is January 6, 2020.

Early bird registartion deadline is January 22, 2020.

Bursary application deadline is March 9, 2020.

Deadline for abstract submission for poster presentation is March 11, 2020.

Standard registration deadline is March 19, 2020.

For more information please contact: 

Organised by:
  • The Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC) (United Kingdom)

April 29-30, 2020
Brunnen, Switzerland

The ‘SCS Conference on Stereochemistry’, better known as ‘Bürgenstock Conference’, is an outstanding international chemistry meeting of high scientific quality, with an optimal setting for intense inter-disciplinary discussion.

Stereochemistry is the principle underlying our understanding of the processes of life and the properties of matter at the molecular level. It is a key element not only in all chemical disciplines, but also in modern molecular biology, molecular medicine, biophysics, and material design. Accordingly, the ‘Bürgenstock Conference’ has grown over the years into a multi-disciplinary conference where frontier science is being discussed. Lectures cover many areas of chemistry and relevant highlights from neighboring disciplines.

For more information please contact: info@scg.ch

Organised by:
  • Division for Medicinal Chemistry & Chemical Biology (DMCCB) (Switzerland)


EFMC Sponsored Event

April 30, 2020
Hatfield, United Kingdom

The Symposium on Medicinal Chemistry in Eastern England, known colloquially as the "Hatfield MedChem" meeting, is a highly successful, long-standing, one-day meeting which runs annually. The scientific program will comprise presentations showcasing medicinal chemistry case studies from tools to candidates, across a range of modalities, therapeutic areas and target classes, as well as covering more general topics from the forefront of drug discovery of relevance to medicinal chemists. The meeting aims to be informal and interactive and the event will offer excellent scientific and networking opportunities for all those working in medicinal chemistry and drug discovery. 

Deadline for abstract submission is December 20, 2019.

For more information please contact: 

Organised by:
  • The Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC) (United Kingdom)